Aspergillus and the paediatric lung

Elpis Hatziagorou, Thomas J. Walsh, John N. Tsanakas, Emmanuel Roilides

Research output: Contribution to journalArticle

Abstract

Aspergillus spp produce a wide range of saprophytic and invasive syndromes in the lungs, including allergic bronchopulmonary aspergillosis (ABPA), aspergilloma and invasive pulmonary aspergillosis (IPA). ABPA results from hypersensitivity to the fungus, and mainly affects patients with asthma or cystic fibrosis (CF). The treatment of choice consists of systemic corticosteroids and itraconazole. Aspergilloma is managed by observation or surgery. IPA is predominantly seen in patients with haematological malignancies, chronic granulomatous disease or immunosuppressive treatment. With the use of aggressive therapies for end-stage CF, such as heart-lung transplantation, the potential for a patient to convert from colonization or ABPA to IPA has increased. Suggestive clinical and radiological findings, supplemented with mycological data using serology and molecular biology, have enhanced the capacity to diagnose IPA in paediatric patients. While voriconazole is considered the first-line therapy in IPA, several other antifungal agents may be appropriate alternatives.

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalPaediatric Respiratory Reviews
Volume10
Issue number4
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Invasive Pulmonary Aspergillosis
Aspergillus
Allergic Bronchopulmonary Aspergillosis
Pediatrics
Lung
Cystic Fibrosis
Heart-Lung Transplantation
Chronic Granulomatous Disease
Itraconazole
Antifungal Agents
Hematologic Neoplasms
Serology
Therapeutics
Immunosuppressive Agents
Molecular Biology
Adrenal Cortex Hormones
Hypersensitivity
Fungi
Asthma
Observation

Keywords

  • Allergic bronchopulmonary aspergillosis
  • Aspergilloma
  • Children
  • Invasive pulmonary aspergillosis
  • Neonates

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Hatziagorou, E., Walsh, T. J., Tsanakas, J. N., & Roilides, E. (2009). Aspergillus and the paediatric lung. Paediatric Respiratory Reviews, 10(4), 178-185. https://doi.org/10.1016/j.prrv.2009.06.006

Aspergillus and the paediatric lung. / Hatziagorou, Elpis; Walsh, Thomas J.; Tsanakas, John N.; Roilides, Emmanuel.

In: Paediatric Respiratory Reviews, Vol. 10, No. 4, 12.2009, p. 178-185.

Research output: Contribution to journalArticle

Hatziagorou, E, Walsh, TJ, Tsanakas, JN & Roilides, E 2009, 'Aspergillus and the paediatric lung', Paediatric Respiratory Reviews, vol. 10, no. 4, pp. 178-185. https://doi.org/10.1016/j.prrv.2009.06.006
Hatziagorou E, Walsh TJ, Tsanakas JN, Roilides E. Aspergillus and the paediatric lung. Paediatric Respiratory Reviews. 2009 Dec;10(4):178-185. https://doi.org/10.1016/j.prrv.2009.06.006
Hatziagorou, Elpis ; Walsh, Thomas J. ; Tsanakas, John N. ; Roilides, Emmanuel. / Aspergillus and the paediatric lung. In: Paediatric Respiratory Reviews. 2009 ; Vol. 10, No. 4. pp. 178-185.
@article{3a633955967d472d819f62753f9eeade,
title = "Aspergillus and the paediatric lung",
abstract = "Aspergillus spp produce a wide range of saprophytic and invasive syndromes in the lungs, including allergic bronchopulmonary aspergillosis (ABPA), aspergilloma and invasive pulmonary aspergillosis (IPA). ABPA results from hypersensitivity to the fungus, and mainly affects patients with asthma or cystic fibrosis (CF). The treatment of choice consists of systemic corticosteroids and itraconazole. Aspergilloma is managed by observation or surgery. IPA is predominantly seen in patients with haematological malignancies, chronic granulomatous disease or immunosuppressive treatment. With the use of aggressive therapies for end-stage CF, such as heart-lung transplantation, the potential for a patient to convert from colonization or ABPA to IPA has increased. Suggestive clinical and radiological findings, supplemented with mycological data using serology and molecular biology, have enhanced the capacity to diagnose IPA in paediatric patients. While voriconazole is considered the first-line therapy in IPA, several other antifungal agents may be appropriate alternatives.",
keywords = "Allergic bronchopulmonary aspergillosis, Aspergilloma, Children, Invasive pulmonary aspergillosis, Neonates",
author = "Elpis Hatziagorou and Walsh, {Thomas J.} and Tsanakas, {John N.} and Emmanuel Roilides",
year = "2009",
month = "12",
doi = "10.1016/j.prrv.2009.06.006",
language = "English (US)",
volume = "10",
pages = "178--185",
journal = "Paediatric Respiratory Reviews",
issn = "1526-0542",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Aspergillus and the paediatric lung

AU - Hatziagorou, Elpis

AU - Walsh, Thomas J.

AU - Tsanakas, John N.

AU - Roilides, Emmanuel

PY - 2009/12

Y1 - 2009/12

N2 - Aspergillus spp produce a wide range of saprophytic and invasive syndromes in the lungs, including allergic bronchopulmonary aspergillosis (ABPA), aspergilloma and invasive pulmonary aspergillosis (IPA). ABPA results from hypersensitivity to the fungus, and mainly affects patients with asthma or cystic fibrosis (CF). The treatment of choice consists of systemic corticosteroids and itraconazole. Aspergilloma is managed by observation or surgery. IPA is predominantly seen in patients with haematological malignancies, chronic granulomatous disease or immunosuppressive treatment. With the use of aggressive therapies for end-stage CF, such as heart-lung transplantation, the potential for a patient to convert from colonization or ABPA to IPA has increased. Suggestive clinical and radiological findings, supplemented with mycological data using serology and molecular biology, have enhanced the capacity to diagnose IPA in paediatric patients. While voriconazole is considered the first-line therapy in IPA, several other antifungal agents may be appropriate alternatives.

AB - Aspergillus spp produce a wide range of saprophytic and invasive syndromes in the lungs, including allergic bronchopulmonary aspergillosis (ABPA), aspergilloma and invasive pulmonary aspergillosis (IPA). ABPA results from hypersensitivity to the fungus, and mainly affects patients with asthma or cystic fibrosis (CF). The treatment of choice consists of systemic corticosteroids and itraconazole. Aspergilloma is managed by observation or surgery. IPA is predominantly seen in patients with haematological malignancies, chronic granulomatous disease or immunosuppressive treatment. With the use of aggressive therapies for end-stage CF, such as heart-lung transplantation, the potential for a patient to convert from colonization or ABPA to IPA has increased. Suggestive clinical and radiological findings, supplemented with mycological data using serology and molecular biology, have enhanced the capacity to diagnose IPA in paediatric patients. While voriconazole is considered the first-line therapy in IPA, several other antifungal agents may be appropriate alternatives.

KW - Allergic bronchopulmonary aspergillosis

KW - Aspergilloma

KW - Children

KW - Invasive pulmonary aspergillosis

KW - Neonates

UR - http://www.scopus.com/inward/record.url?scp=76549135136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549135136&partnerID=8YFLogxK

U2 - 10.1016/j.prrv.2009.06.006

DO - 10.1016/j.prrv.2009.06.006

M3 - Article

C2 - 19879507

AN - SCOPUS:76549135136

VL - 10

SP - 178

EP - 185

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

SN - 1526-0542

IS - 4

ER -